Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Adial Pharmaceuticals (ADIL) Non Operating Income (2022 - 2024)

Adial Pharmaceuticals' Non Operating Income history spans 3 years, with the latest figure at -$75000.0 for Q4 2024.

  • For Q4 2024, Non Operating Income fell 194.07% year-over-year to -$75000.0; the TTM value through Dec 2024 reached -$75043.0, down 186.88%, while the annual FY2025 figure was $164854.0, 319.68% up from the prior year.
  • Non Operating Income for Q4 2024 was -$75000.0 at Adial Pharmaceuticals, down from $4.8 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $4.8 million in Q3 2024 and bottomed at -$4.6 million in Q1 2024.
  • The 3-year median for Non Operating Income is $19564.0 (2023), against an average of $24628.6.
  • The largest YoY upside for Non Operating Income was 46818.36% in 2024 against a maximum downside of 16130.52% in 2024.
  • A 3-year view of Non Operating Income shows it stood at $47821.0 in 2022, then soared by 66.71% to $79724.0 in 2023, then plummeted by 194.07% to -$75000.0 in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Non Operating Income are -$75000.0 (Q4 2024), $4.8 million (Q3 2024), and -$171068.0 (Q2 2024).